Benjamin Graham · Inversión deep-value defensiva
Is Arbutus Biopharma Corporation (ABUS) a Benjamin Graham Stock?
Meets only 4/7 Graham criteria, likely overpriced or unstable.
43/100
No encaja
4/7 criterios cumplidos
Los criterios de Benjamin Graham, aplicados a ABUS
P/E ≤ 15
clave5.1x
P/B ≤ 1.5
clave3.1x
Current ratio ≥ 2
-
Debt / Equity ≤ 1
0.0x
Cómo se valora ABUS en otras estrategias
Datos financieros en vivo
Cap. mercado
$682.08M
PER (TTM)
5.1x
ROIC (TTM)
56.72%
Margen bruto
99.98%
Otros análisis Benjamin Graham
Preguntas frecuentes
What is ABUS's Benjamin Graham fit score?
ABUS scores 43/100 on our Benjamin Graham fit engine. Meets only 4/7 Graham criteria, likely overpriced or unstable.
Does Benjamin Graham actually own ABUS?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends ABUS.
How often is this score updated?
ABUS's Benjamin Graham fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Benjamin Graham posea o recomiende ABUS personalmente.
